Pharmacokinetics of intravenous glycyrrhizin after single and multiple doses in patients with chronic hepatitis C infection - PubMed (original) (raw)
Clinical Trial
Pharmacokinetics of intravenous glycyrrhizin after single and multiple doses in patients with chronic hepatitis C infection
T G van Rossum et al. Clin Ther. 1999 Dec.
Abstract
Intravenous glycyrrhizin has been used in Japan for the treatment of chronic hepatitis for >20 years, although only a few reports of its pharmacokinetic profile after multiple intravenous doses in small numbers of Japanese patients have been published. The present study compared these Japanese data against the pharmacokinetic characteristics of glycyrrhizin after single and multiple intravenous doses in 35 European patients with chronic hepatitis C infection. We administered 80, 160, or 240 mg glycyrrhizin 3 times/wk or 200 mg glycyrrhizin 6 times/wk for 4 weeks. Twenty-four-hour pharmacokinetic assessments were performed on day 1 and on or around day 14. Glycyrrhizin levels were determined by high-performance liquid chromatography. The mean (+/- SD) volume of distribution at steady state on day 1 in the 80-, 160-, 200-, and 240-mg groups were 67 +/- 11, 62 +/- 13, 54 +/- 7, and 66 +/- 8 mL/kg, respectively. The respective terminal elimination half-lives on day 1 were 7.7 +/- 2.8, 10.1 +/- 1.4, 9.0 +/- 2.3, and 8.6 +/- 2.1 hours. The area under the curve (AUC) increased linearly with doses < or =200 mg (r = 0.67; P < 0.001). No significant differences between day 1 and day 14 were found in any dose group, with the exception of AUC in the 200-mg group, which was significantly higher on day 14 compared with day 1 (P = 0.03). Comparing the European and Japanese data, the mean (+/- SD) AUC was 289 +/- 244 microg/h per mL for the former and 402 +/- 372 microg/h per mL for the latter; the half-life was 8.2 +/- 2.6 versus 8.8 +/- 9.0 hours; and the total clearance was 7.6 +/- 3.6 versus 8.5 +/- 5.7 mL/h per kg. Thus our pharmacokinetic data are comparable to those from Japan. Glycyrrhizin's pharmacokinetics are linear up to 200 mg. Drug accumulation is seen after 2 weeks of treatment with 200 mg administered 6 times/wk.
Similar articles
- [The pharmacokinetics of the glycyrrhizin and glycyrrhetic acid after intravenous administration of glycyrrhizin for the patients with chronic liver disease caused by type C hepatitis virus].
Takahashi M, Nakano S, Takeda I, Kumada T, Sugiyama K, Osada T, Kiriyama S, Toyoda H, Shimada S, Samori T. Takahashi M, et al. Nihon Shokakibyo Gakkai Zasshi. 1995 Dec;92(12):1929-36. Nihon Shokakibyo Gakkai Zasshi. 1995. PMID: 8558777 Japanese. - The relationship between pharmacokinetic behaviour of glycyrrhizin and hepatic function in patients with acute hepatitis and liver cirrhosis.
Yamamura Y, Tanaka N, Santa T, Kotaki H, Aikawa T, Uchino K, Osuga T, Sawada Y, Iga T. Yamamura Y, et al. Biopharm Drug Dispos. 1995 Jan;16(1):13-21. doi: 10.1002/bdd.2510160103. Biopharm Drug Dispos. 1995. PMID: 7711280 Clinical Trial. - Intravenous glycyrrhizin for the treatment of chronic hepatitis C: a double-blind, randomized, placebo-controlled phase I/II trial.
van Rossum TG, Vulto AG, Hop WC, Brouwer JT, Niesters HG, Schalm SW. van Rossum TG, et al. J Gastroenterol Hepatol. 1999 Nov;14(11):1093-9. doi: 10.1046/j.1440-1746.1999.02008.x. J Gastroenterol Hepatol. 1999. PMID: 10574137 Clinical Trial. - Review article: glycyrrhizin as a potential treatment for chronic hepatitis C.
van Rossum TG, Vulto AG, de Man RA, Brouwer JT, Schalm SW. van Rossum TG, et al. Aliment Pharmacol Ther. 1998 Mar;12(3):199-205. doi: 10.1046/j.1365-2036.1998.00309.x. Aliment Pharmacol Ther. 1998. PMID: 9570253 Review. - [Novel formulations of a liver protection drug glycyrrhizin].
Koga K, Kawashima S, Shibata N, Takada K. Koga K, et al. Yakugaku Zasshi. 2007 Jul;127(7):1103-14. doi: 10.1248/yakushi.127.1103. Yakugaku Zasshi. 2007. PMID: 17603270 Review. Japanese.
Cited by
- Oncopreventive and oncotherapeutic potential of licorice triterpenoid compound glycyrrhizin and its derivatives: Molecular insights.
Jain R, Hussein MA, Pierce S, Martens C, Shahagadkar P, Munirathinam G. Jain R, et al. Pharmacol Res. 2022 Apr;178:106138. doi: 10.1016/j.phrs.2022.106138. Epub 2022 Feb 19. Pharmacol Res. 2022. PMID: 35192957 Free PMC article. Review. - Can Antiviral Activity of Licorice Help Fight COVID-19 Infection?
Diomede L, Beeg M, Gamba A, Fumagalli O, Gobbi M, Salmona M. Diomede L, et al. Biomolecules. 2021 Jun 8;11(6):855. doi: 10.3390/biom11060855. Biomolecules. 2021. PMID: 34201172 Free PMC article. Review. - Glycyrrhizin Effectively Inhibits SARS-CoV-2 Replication by Inhibiting the Viral Main Protease.
van de Sand L, Bormann M, Alt M, Schipper L, Heilingloh CS, Steinmann E, Todt D, Dittmer U, Elsner C, Witzke O, Krawczyk A. van de Sand L, et al. Viruses. 2021 Apr 2;13(4):609. doi: 10.3390/v13040609. Viruses. 2021. PMID: 33918301 Free PMC article. - Exploring the Pivotal Immunomodulatory and Anti-Inflammatory Potentials of Glycyrrhizic and Glycyrrhetinic Acids.
Richard SA. Richard SA. Mediators Inflamm. 2021 Jan 7;2021:6699560. doi: 10.1155/2021/6699560. eCollection 2021. Mediators Inflamm. 2021. PMID: 33505216 Free PMC article. Review. - Synthesis and structure-activity relationship studies of water-soluble β-cyclodextrin-glycyrrhetinic acid conjugates as potential anti-influenza virus agents.
Liang S, Li M, Yu X, Jin H, Zhang Y, Zhang L, Zhou D, Xiao S. Liang S, et al. Eur J Med Chem. 2019 Mar 15;166:328-338. doi: 10.1016/j.ejmech.2019.01.074. Epub 2019 Jan 30. Eur J Med Chem. 2019. PMID: 30731401 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources